Chemocentric Chemoimmunotherapy: A New Concept in Melanoma Immunotherapy
Paul Howell,Soroosh Radfar,Yixiang Wang,Hung Khong
DOI: https://doi.org/10.5772/20018
2011-01-01
Abstract:IntroductionAccording to the American Cancer Society, 68,130 new cases of melanoma and 8,700 deaths were predicted for 2010 (Jemal et al., 2010).Although melanoma comprises only 5% of all skin cancers, it is by far the deadliest, responsible for 75% of skin cancer-related deaths, and its incidence is steadily increasing worldwide.Primary cutaneous melanoma has an excellent outcome with early surgical intervention, but regional and distant metastatic disease have a much more dismal prognosis.Current five-year survival rates equal 91% for all disease sites, including 98% for local disease, 62% for regional disease (including regional lymph node involvement), and only 15% for those with distant metastasis (median survival is only 7.5 months).Unfortunately, for those patients who will develop locally advanced and metastatic melanoma, current treatment options are limited in scope and effectiveness; thus, the overall poor mortality rates for these patients emphasize the need for better treatment modalities, methods of relapse prevention and earlier recognition of preneoplastic and neoplastic cells (Atallah & Flaherty, 2006; Balch et al., 2001a Balch et al., , 2001b;;Blesa et al., 2011).Currently, there are no curative therapies for metastatic melanoma.Until March 25, 2011, the U.S. Food and Drug Administration (FDA) had only approved two drugs for the treatment of metastatic melanoma, the DNA alkylating agent dacarbazine and high-dose Interleukin-2 (IL-2).Dacarbazine alkylates and crosslinks DNA in all phases of the cell cycle, impairing DNA function, inducing cell-cycle arrest and apoptosis (Bajetta et al., 2002), and is a common chemotherapeutic option for multiple cancers (Seam et al., 2009;Yang & Chapman, 2009).IL-2 activates endogenous anti-tumor-reactive T cells and natural killer (NK) cells.Notably, circulating NK cells from stage IV melanoma patients were recently shown to exhibit a unique phenotypic and functional character toward melanoma cells, and this unique character was altered in patients after treatment with chemotherapy (Fregni et al., 2011).Dacarbazine induces objective tumor regression in 15-20% of metastatic melanoma patients with a median survival of only 8-9 months and a 2-3% complete response rate, and single agent bolus IL-2, while providing a 20-30% objective response rate, creates significant long-term response in only 5% of patients treated, is fraught with toxicity and costly.Combination low-dose IL-2 and chemotherapy and single-agent high-dose IL-2 produce a www.intechopen.com